Results 101 to 110 of about 14,040 (225)

Fibrates and coronary risk reduction

, 2020
Many medications are currently available to correct lipoprotein abnormalities when lifestyle measures alone are not sufficient. No single agent or class of agents is able to correct all of the lipoprotein abnormalities. This paper reviews the role of one
George Steiner
core  

Diabetic Peripheral Neuropathy: Molecular Staging, Risk Factors, Therapeutics, and Emerging Trends

Med Research, Volume 2, Issue 2, Page 309-342, June 2026.
The heterogeneous landscape of DPN can be unified through a tripartite pathogenic model encompassing progressive stages of metabolic dysregulation, chronic inflammation, and overt neuronal damage. Within this framework, six clinical subtypes were identified, namely, hyperglycemia‐driven, dyslipidemia‐driven, inflammation‐driven, dysvascularity‐driven ...
Xiaofeng Dai, Mingze Tang
wiley   +1 more source

Management of dyslipidemias with fibrates, alone and in combination with statins: role of delayed-release fenofibric acid

, 2010
Elisavet Moutzouri, Anastazia Kei, Moses S Elisaf, Haralampos J MilionisDepartment of Internal Medicine, School of Medicine, University of Ioannina, Ioannina, GreeceAbstract: Cardiovascular disease (CVD) represents the leading cause of mortality ...
Moses S Elisaf, et al, Elisavet Moutzouri, Anastazia Kei   +3 more
core  

Opposite metabolic response to fenofibrate treatment in pregnant and virgin rats

Journal of Lipid Research, 2002
The level of maternal circulating triglycerides during late pregnancy has been correlated to newborns' weight in humans. To investigate the response to fenofibrate, a hypotriglyceridemic agent, in pregnant rats, 0, 100, or 200 mg of fenofibrate/kg body ...
Ana Soria, Carlos Bocos, Emilio Herrera
doaj   +1 more source

AEG‐AESPANC‐OPGE‐SIED‐SPG Ibero‐Latin American Guidelines on Acute Pancreatitis (iLATAM‐AP)

United European Gastroenterology Journal, Volume 14, Issue 5, June 2026.
ABSTRACT Introduction Acute pancreatitis (AP) is a major cause of gastrointestinal hospitalizations worldwide. Although typically self‐limiting, up to one‐third of cases develop complications associated with increased morbidity and mortality. Despite recent advances that have improved outcomes, clinical heterogeneity necessitates updated, evidence ...
Karina Cárdenas‐Jaén, Lucía Guilabert, Emma Martínez‐Moneo, Carla Mancilla, Miguel Bispo, Pedro Moutinho‐Ribeiro, Rodrigo Mansilla, Andreia Rei, Ana García García de Paredes, Antonio López‐Serrano, Bruno Rosa, Claudia Sánchez‐Marín, Daniel de la Iglesia, Edson Guzmán‐Calderon, Eduardo Rodrigues‐Pinto, Eva Marín‐Serrano, Fabio Ausania, Fauze Maluf‐Filho, Guido Villagómez, Humberto Cristino, Isabel Pascual‐Moreno, José A. Gonzalez, José M. Ramia, João Lopes‐Delgado, Lucas Granero, Mario Peláez‐Luna, María Francisco, Natalia Corzo‐Zamora, Ricardo Rio‐Tinto, Rómulo D. Vargas, Sandra Basso, Susana Lopes, Susana Marques, William Manzanares, Zoltán Berger, Irene Carrillo, José Joaquín Mira‐Solves, Alberto Espino, Adriana Cowdin, Alejandro Piscoya, Alexandra Fernandes, Noelia Rodríguez‐Ferreiro, Neftalí Jara Pérez‐López, Beatriz Valero, Enrique de‐Madaria   +44 more
wiley   +1 more source

Severe decrease in high-density lipoprotein cholesterol with the combination of fibrates and ezetimibe: A case series

, 2017
A sudden and severe drug-induced decrease in plasma high-density lipoprotein cholesterol (HDL-C) is a rare condition. We report 2 patients with familial hypercholesterolemia treated with statins and fibrates and 2 others with mixed dyslipidemia treated ...
Krempf, Michel, Nobecourt, Estelle, Cariou, Bertrand, Lambert, Gilles   +3 more
core   +1 more source

The Pleiotropic Effects of Lipid-Modifying Interventions: Exploring Traditional and Emerging Hypolipidemic Therapies

Metabolites
Atherosclerotic cardiovascular disease poses a significant global health issue, with dyslipidemia standing out as a major risk factor. In recent decades, lipid-lowering therapies have evolved significantly, with statins emerging as the cornerstone ...
Dimitris Kounatidis, Nikolaos Tentolouris, Natalia G. Vallianou, Iordanis Mourouzis, Irene Karampela, Theodora Stratigou, Eleni Rebelos, Marina Kouveletsou, Vasileios Stamatopoulos, Eleni Tsaroucha, Maria Dalamaga   +10 more
doaj   +1 more source

Sex‐Specific Associations of Inflammatory Biomarkers With All‐Cause and Cardiovascular Mortality Across Glycaemic Status: A Prospective UK Biobank Study

Diabetes, Obesity and Metabolism, Volume 28, Issue 6, Page 4728-4740, June 2026.
ABSTRACT Aims To explore sex‐specific heterogeneity in the prognostic discrimination of inflammatory markers for mortality across different glycaemic states. Methods This prospective cohort study included 450 438 participants from the UK Biobank (median follow‐up: 15.3 years), stratified by sex and glycaemic status.
Yawen Zhang, Menghan Li, Manrong Xu, Yun Shen, Lianxi Li, Gang Hu   +5 more
wiley   +1 more source

Fibrates down-regulate hepatic scavenger receptor class B type I protein expression in mice

, 2003
Fibrates are normolipidemic drugs used in atherogenic dyslipidemia because of their ability to raise high density lipoprotein (HDL) and decrease triglyceride levels.
Kozarsky, KF, Rigotti, A, Mardones, P, Nishimoto, T, Miquel, JF, Bouly, M, Luc, G, Clavey, V, Staels, B, Duran, D, Pilon, A, Arai, H, Altayo, M   +12 more
core   +1 more source

Statin Therapy for Primary Prevention and Clinical Outcomes in Adults Aged 80 and Older: A Retrospective Comparative Cohort Study

Journal of the American Geriatrics Society, Volume 74, Issue 6, Page 1687-1691, June 2026.
ABSTRACT Background Evidence supporting the use of statins for primary prevention of cardiovascular disease (CVD) in individuals aged ≥ 80 years remains limited. This study aimed to evaluate the long‐term clinical benefits and safety of statins for primary prevention in patients aged 80 years and older.
Ophir Lavon, Wafaa Hamodi, Sameer Kassem
wiley   +1 more source